Roche Shows Interest in This Small-Cap Biotech. Should You?
An emerging therapeutic area continues to draw interest from large drugmakers. The first half of 2022 hasn't been kind to biotech stocks, but the pain has been especially acute for…
An emerging therapeutic area continues to draw interest from large drugmakers. The first half of 2022 hasn't been kind to biotech stocks, but the pain has been especially acute for…